Biotech News

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

ImmunityBio (IBRX)ImmunityBioCommercial

Senior leadership will discuss ImmunityBio’s clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 10, 2026-- ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company,

Related news

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

Stock data

Close
6.57 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States